It is a comprehensive pharmaceutical enterprise with multi-dosage production capacity and all-round drug R&D capabilities, integrating R&D/production/sales of Chinese and Western APIs and preparations
Sichuan Meidakang Huakang Pharmaceutical Co., Ltd. is a chemical pharmaceutical enterprise integrating R&D, production and sales, which is jointly invested by Beijing Jinyuan Yaoye Pharmaceutical Technology Co., Ltd., Sichuan Meidakang Pharmaceutical Group and Sichuan Jiannanchun Group. The company is located in Jiangsu Industrial Park, Mianzhu Economic Development Zone, Sichuan.
The company's dosage form products are complete, covering lyophilized powder injection, sterile powder injection, large-volume injection, small-volume injection, eye drops, solutions (including nebulized inhalation), tablets, capsules, external liniments and chemical APIs. At present, there are more than 120 drug approval numbers, more than 70 national essential drug varieties, 12 new drug certificates (including three first-class new drug certificates), the main varieties are the production and sales of antibacterial drugs (antibacterial, fungal, anaerobic bacteria), antiviral drugs, vitamins, antipyretic analgesia and other treatment categories, especially the latest anti-deep fungal infection drug - voriconazole, anti-hepatitis B virus drug - adefovir disoproxil occupies a leading position in similar products in China.
In 2012, the company invested 300 million yuan in technological transformation to build a comprehensive pharmaceutical production plant of more than 40,000 square meters, and cooperated with Beijing Furui Kangzheng Pharmaceutical Technology Research Institute and Shandong Daguan Pharmaceutical Technology Research Institute to lay out ten major therapeutic areas as the direction, with the goal of precision treatment of frequent diseases, common diseases and rare diseases, and targeted anti-cancer drugs, immunodeficiency treatment drugs, antibacterial drugs, respiratory drugs, and non-cytotoxic small molecule targeted anticancer drugs, immunodeficiency treatment drugs, antibacterial drugs, respiratory drugs, As of June 2016, 42 new drugs have been declared, 32 clinical approvals have been obtained, and 26 varieties are in BE and clinical research. Huakang Pharmaceutical has the production capacity of multi-dosage varieties and a full range of drug research and development capabilities, and in the next 3~5 years, Huakang Pharmaceutical will enter the road of high-speed and sustainable development.
In the future, Sichuan Meidakang Huakang Pharmaceutical Co., Ltd. will firmly take the road of innovative products and innovative development, focus on new drug research and development and market promotion, continue to improve the production quality management system, and seek new leapfrog development.
